IRF1 and neoplasm: Since tumor proliferation rate is the major determinant of survival among patients with ER+ disease we sought evidence for the growth suppressive RelA-IRF1-CDK4 axis by analyzing expression profiles of NFKBIA (IkB-α), a surrogate for RelA activity, AURKA, and the interferon factors in ER+/HER2- tumors analyzed by TCGA.